Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyAetna Vulvodynia Treatments Coverage Update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0759

    Vulvodynia and Vulvar Vestibulitis Treatments

    Customize your policy alerts

    Sign up for Aetna Policy 0759 alerts

    Get alerted when Policy 0759 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for treatments of vulvodynia/vulvar vestibulitis for insured members, listing medically necessary interventions and those considered experimental/investigational.

    Policy Summary
    PayerAetna
    PolicyVulvodynia and Vulvar Vestibulitis Treatments
    Policy CodePolicy 0759
    Change TypeAdministrative review — no material change
    Effective DateJul 1, 2008
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionObtain and document failure of appropriate conservative therapies (e.g., vulvar care, physical therapy, pharmacotherapy) before approving vestibulectomy or other surgical interventions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3medically necessary
    32experimental/investigational
    N94.810-819ICD-10 referenced
    56620-56810Representative CPT ranges
    73.6%vestibulectomy complete response

    Coverage Criteria for Vulvodynia and Vulvar Vestibulitis

    inv-01: Medically necessary — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Medically necessary treatments: Physical therapy; Perineoplasty; Vestibulectomy (local or total) for persons who have failed conservative measures (including vulvar care, physical therapy, pharmacotherapy including analgesics).

    Vestibulectomy specified as for those who have failed conservative measures

    inv-02: Experimental and Investigational — Not covered / Experimental and investigational

    Not covered / Experimental and investigational

    Experimental / investigational interventions: Acupuncture; Aromatherapy; Botulinum toxin; Cannabis; Compound medications (e.g., compounded bioidentical hormones and retinoid compounds); Extracorporeal shock-wave therapy; Ganglion impar block (Impar node infiltration); Hypnotherapy; Internal manipulation (transvaginal/transrectal); Interferon; Laser therapy/surgery (fractional CO2/micro-ablative CO2, HILT, Ladylift non-ablative laser, low-level laser, YAG); Low-intensity shockwave therapy; Manual perineal rehabilitation with lidocaine 2% gel; Montelukast; Neural therapy; Palmitoylethanolamide; Peripheral subcutaneous vulvar field stimulation; Pelvic floor biofeedback; Photodynamic therapy; Pudendal nerve decompression; Pulsed radiofrequency therapy; Sacral neuromodulation; Spinal cord stimulation; Topical baclofen; Topical meloxicam; Topical nifedipine; Topical nitroglycerin; Topical testosterone; Transcranial direct current stimulation; Vaginal acupressure (Hippocratic pelvic massage); Vestibuloplasty; Vulvar emulgel Meclon Lenexis.
    Policy Summary
    PayerAetna
    PolicyVulvodynia and Vulvar Vestibulitis Treatments
    Policy CodePolicy 0759
    Change TypeAdministrative review — no material change
    Effective DateJul 1, 2008
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionObtain and document failure of appropriate conservative therapies (e.g., vulvar care, physical therapy, pharmacotherapy) before approving vestibulectomy or other surgical interventions.
    SourceLink
    On This Page
    Coverage Criteria for Vulvodynia and Vulvar VestibulitisCoding — Codes and Diagnosis CriteriaProvider Actions, Prior Authorization, and DocumentationBackground on Condition and TreatmentsDefinitions and TerminologyPolicy Revision History

    Listed as experimental/investigational because effectiveness not established for vulvodynia/vulvar vestibulitis

    inv-03: Surgical intervention (vestibulectomy/local excision) criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Conservative therapy failure: Documented failure of appropriate conservative therapies (topical/oral medications, physical therapy, biofeedback, guided nerve blocks) prior to surgical interventions.

    ASCCP/ACOG indicate surgery is last resort

    Localized refractory symptoms for excisional surgery: Pain localized to the vestibule confirmed by examination (e.g., cotton swab test) and refractory to prior treatments.

    Local excision/vestibulectomy indicated for localized, refractory disease

    Informed consent and counseling: Patient counseling regarding variable outcomes and potential complications (e.g., decreased lubrication, cysts) and discussion of alternative therapies prior to surgery.

    Studies report complications but generally high satisfaction rates; document cotton-swab localization

    inv-04: Medications and alternative therapies — insufficient evidence / investigational

    Considered investigational/insufficient evidence when ANY of the following apply

    Medications with placebo-level evidence: Topical lidocaine, oral desipramine, and topical nifedipine demonstrated no significant benefit over placebo in randomized trials.

    Foster et al and Bornstein et al report no superiority to placebo

    Novel/alternative therapies with limited data: Acupuncture, hypnotherapy, botulinum toxin A, photodynamic therapy, neuromodulation, pulsed radiofrequency, multi-level nerve blocks, and other small pilot modalities have preliminary or small-sample evidence but lack large RCT confirmation.

    Multiple small studies and pilot trials reported promising results but require larger controlled studies

    Antidepressants / anticonvulsants: Evidence is insufficient to support routine recommendation for TCAs and anticonvulsants as effective monotherapies; trials are few or negative (e.g., desipramine, gabapentin ER).

    Brown et al RCT and other reviews conclude inadequate or mixed evidence

    inv-05: Evidence-based stance and treatment hierarchy — summary of guidance and recommended approach from cited reviews/guidelines

    Summary of guidance and recommended approach from cited expert reviews and guidelines in these chunks

    Multidisciplinary first-line approach: Recommend multidisciplinary care including psychological interventions, pelvic floor physical therapy, and conservative medical management as primary treatments for vulvodynia/ PVD.

    Supported by expert reviews and guideline excerpts (Goldstein et al; Thofner et al)

    Second-line or conditional therapies: Capsaicin, botulinum toxin, and interferon may be considered as second-line options but require further evidence; botulinum toxin is often not covered and is expensive.

    Expert committee suggested as second-line pending more research

    Laser therapies (micro-ablative fractional CO2, Er:YAG, HILT, Ladylift, low-level lasers) are not recommended for routine clinical practice for vulvodynia outside well-designed clinical trials or special governance due to limited, heterogeneous evidence and lack of long-term safety data.

    Preti et al 2019 best practice document cautions routine use

    Interventional novelties with preliminary evidence: Radiofrequency (pulsed/cooled), peripheral vulvar field stimulation, topical compounded agents, and ESWT have preliminary positive reports (case series, pilot studies, single small RCT for ESWT) but need further validation before routine adoption.

    Multiple small studies and case reports summarized; evidence limited

    inv-06: Evidence summaries by intervention — summaries and inferred coverage stance by intervention

    Summary of evidence and inferred coverage stance by intervention

    Laser therapies (HILT and LLLT): Evidence is limited and heterogeneous; HILT shows promising pain reduction in related chronic pain conditions but data specific to vulvodynia are insufficient; LLLT pilot RCT (n=34) reported improvement on one clinical measure but inconsistent effects across outcomes and requires larger trials.

    Heterogeneous protocols and short follow-up limit conclusions

    Ganglion impar block: Small case series (n=8) and case reports suggest short-term pain reduction with anesthetic infiltrations; CT guidance may improve accuracy in fibrotic tissue; evidence level IV and requires RCT validation.

    Document imaging guidance and outcome measures when used

    Transcranial direct-current stimulation: A triple-blind RCT (n=40) found no significant benefit of active stimulation over sham for intercourse pain or secondary outcomes.

    Does not support routine use

    Gabapentin (extended-release): A randomized, multicenter double-blind placebo-controlled cross-over trial (n=89) found gabapentin did not significantly reduce tampon test pain, intercourse pain, or daily pain versus placebo.

    Findings do not support gabapentin alone as treatment for vulvodynia

    Botulinum toxin (BTX-A): Observational follow-up (n=109, 79 completed) of EMG-guided levator ani injections reported reduced dyspareunia and improved QOL at 6 months in refractory localized provoked vulvodynia; randomized trials are needed.

    Promising observational data but insufficient RCT evidence

    Topical meloxicam + lidocaine: Early case observations reported subjective improvements but with burning/stinging side effects; evidence is preliminary and requires larger studies.

    Small sample sizes; not definitive

    Vaginal dilators: Small observational study (n=15) reported improved dyspareunia and sexual function scores but findings were confounded by adjunctive therapies and not widely endorsed in reviews.

    Limited observational evidence

    Cannabis / PEA-containing agents: Survey and cohort data show some reported pain relief; RCTs and heterogeneity of formulations limit definitive conclusions; counseling about lack of robust evidence is advised.

    Heterogeneous delivery and formulations limit interpretation

    Low-intensity shockwave therapy (LI-SWT): A single prospective double-blind RCT (n=32) reported clinically significant and sustained reductions in dyspareunia and improved pain threshold and sexual function up to 3 months; single-center and small sample size limit generalizability.

    Promising but limited RCT evidence

    Non-pharmacologic preferred options: Psychological therapy, pelvic floor physical therapy, and vestibulectomy (for selected provoked vestibulodynia) have the strongest support and should be considered foundational treatments.

    Supported by multiple reviews and expert consensus

    inv-07: Emerging and investigational therapies — evidence synopsis

    Evidence summary and conditions under which these emerging therapies have been evaluated

    General evidence context: Most studies cited are small, often single-center, and many are pilot, single-arm, or case-series; some randomized trials exist but sample sizes remain limited.

    Small samples and short follow-up are common limitations

    Interventions with reported positive short-term outcomes: Low-intensity shockwave therapy (RCT n=32) showed reductions in VAS dyspareunia and improved algometer thresholds; neural therapy case-series (n=5) and manual perineal rehabilitation with lidocaine (single-arm n=68) reported symptom improvements; Ladylift laser (cohort n=18) and Meclon Lenex vulvar emulgel (RCT n=40) reported symptomatic benefit in small studies.

    Authors frequently note limitations and call for larger RCTs and longer follow-up

    Evidence limitations relevant to coverage: Small sample sizes, short follow-up intervals, single-center designs, lack of active controls in some studies, and heterogeneity of outcome measures limit generalizability and durability conclusions for emerging therapies.

    These limitations reduce confidence for routine coverage

    The policy lists specific CPT, HCPCS and J‑codes that are identified as not covered for the indications in this bulletin. Not‑covered CPT ranges and examples include 0101T (extracorporeal shock wave involving the musculoskeletal system, high energy), 56800 (plastic repair of introitus), and neurostimulation/spinal cord stimulation implantation and generator codes such as 63650, 63655, and 63685. Codes for ganglion impar block and related neurostimulation include 64520, 64550, 64561, and 64581, and chemodenervation/neuromodulation codes such as 64614 and 64630 are listed among not‑covered CPT codes.

    The HCPCS / J‑code list and miscellaneous not‑covered or noted drug/device codes include botulinum toxin entries J0585 (botulinum toxin type A) and J0587 (botulinum toxin type B); multiple interferon codes such as J1826, J1830, and J9212–J9216 (and associated Q‑codes Q3027/Q3028); the compounded drug category J7999; and low‑level laser modality code S8948 (low‑level laser, each 15 minutes).

    Representative CPT groups that are covered when selection criteria are met (for comparison and coding context) include vulvectomy and related surgical codes 56620–56640, perineoplasty 56810, and rehabilitation/therapy ranges 97010–97039 and 97110–97139 (physical medicine and therapeutic procedures). ICD‑10 diagnostic codes covered when selection criteria are met are listed as N94.810 – N94.819 (vulvodynia).

    Vestibuloplasty — defined here as denervation of the vestibule without excision of the painful tissue — has been reported to be ineffective and is not recommended. The 2005 ASCCP guideline noted that vestibuloplasty has shown poor outcomes and therefore is not a preferred surgical approach for vulvodynia.

    Routine use of laser therapies (including micro‑ablative fractional CO2, Er:YAG, high‑intensity laser therapy, Ladylift non‑ablative lasers and related modalities) for vulvodynia or lichen sclerosus is not recommended for routine clinical practice outside of well‑designed clinical trials or special governance arrangements due to limited and low‑quality evidence and insufficient long‑term safety data.

    Laser treatments suffer from heterogeneous and poorly reported protocols, short follow‑up, and methodological limitations that preclude robust conclusions about optimal parameters or lasting benefit. Because studies vary widely in device settings and reporting, evidence is insufficient to endorse specific laser protocols for vulvodynia.

    Several studies of emerging modalities explicitly describe their findings as preliminary, citing small sample sizes and brief observation periods. Authors of the Ladylift non‑ablative laser study specifically noted the small sample (n = 18) and short follow‑up (7–30 days) and stated that results should be considered preliminary pending larger samples and longer‑term follow‑up.

    This Clinical Policy Bulletin is provided to assist in the administration of plan benefits and is neither an offer of coverage nor medical advice. It contains a partial, general description of plan or program benefits and does not constitute a contract. Treating providers are responsible for medical care decisions; Aetna may update the bulletin and it is subject to change.

    Interventions designated in this bulletin as experimental and investigational are considered not medically necessary for the treatment of vulvodynia/vulvar vestibulitis because their effectiveness for this indication has not been established. The policy lists multiple such interventions (see experimental and investigational list) that are therefore not supported for routine coverage.

    Randomized controlled trials have not demonstrated superiority of several topical or oral monotherapies over placebo. For example, a randomized trial comparing topical lidocaine and oral desipramine (alone or combined) found no significant advantage over placebo for tampon‑test pain reduction, and a double‑blind trial of topical nifedipine found no benefit beyond placebo; these findings indicate that topical nifedipine, topical lidocaine, and oral desipramine monotherapy were not superior to placebo in RCTs.

    Several interventions lack sufficient high‑quality evidence of safety and efficacy to support routine use. Examples called out in guideline and review summaries include heterogeneous laser protocols (insufficient standardized parameters) and botulinum toxin, for which evidence is limited to case reports and small trials; botulinum toxin is also often not covered by insurers for this indication.

    Randomized controlled trials summarized in the bulletin found no clear benefit for some neuromodulation or anticonvulsant interventions. A triple‑blind RCT of transcranial direct‑current stimulation found active stimulation was not more effective than sham for intercourse pain or secondary outcomes, and a multicenter double‑blind placebo‑controlled cross‑over trial of extended‑release gabapentin (n = 89) did not show significant reduction in tampon‑test pain, intercourse pain, or daily pain versus placebo.

    Interventions supported only by small, short‑term studies — including some pilot laser studies, small device trials, and limited observational series — should be considered investigational until corroborated by larger randomized trials with longer follow‑up. The policy notes that such preliminary evidence may not be generalizable and warrants further validation.

    Coding — Codes and Diagnosis Criteria

    CPT codes covered if selection criteria are metCPTCovered
    56620-56640Vulvectomy
    56810Perineoplasty, repair of perineum, nonobstetrical (separate procedure)
    97010-97032, 97034-97039Physical medicine and rehabilitation modalities
    97110-97139Physical medicine and rehabilitation therapeutic procedures
    CPT codes not covered for indications listed in the CPBCPTNot Covered
    0101TExtracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy
    56800Plastic repair of introitus
    63650Percutaneous implantation of neurostimulator electrode array, epidural
    63655Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural
    63685Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling
    64520Injection, anesthetic agent; lumbar or thoracic [ganglion impar block]
    64550Application of surface (transcutaneous) neurostimulator
    64561Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed
    64581Incision for implantation of neurostimulator electrodes; sacral nerve (transforaminal placement)
    64614Chemodenervation of muscle(s); extremity and/or trunk muscle(s)
    1–10 of 18
    1/2
    HCPCS / J-codes / miscellaneous not covered or notedHCPCSNot Covered
    J0585Botulinum toxin type A, per unit
    J0587Botulinum toxin type B, per 100 units
    J1826Injection, interferon beta-1a, 30 mcg
    J1830Injection interferon beta-1b, 0.25 mg
    J7999Compounded drug, not otherwise classified
    J9212-J9216Various interferon injections listed
    Q3027, Q3028Interferon beta-1a injections (intramuscular/subcutaneous)
    S8948Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes
    ICD-10 codes covered if selection criteria are metICD-10Covered
    N94.810 - N94.819Vulvodynia [vulvodynia and vulvar vestibulitis]
    inv-23: Duration for diagnosis — clinical threshold for vulvodynia (> 3 months)
    Required symptom duration> 3 months
    Symptoms includedBurning, stinging, irritation, or rawness of the vulva
    Exclusion of other causesDiagnosis after infectious or dermatologic causes have been ruled out

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization / coverage review for listed CPT/HCPCS/J‑codes

    Certain CPT, HCPCS and J‑codes listed as not covered for the indications in this bulletin may trigger claim denial or require coverage review; prior authorization may be required when these services are proposed. Examples include extracorporeal shock wave (0101T), plastic repair of introitus (56800), ganglion impar block (64520), various neurostimulation and spinal cord stimulation codes (e.g., 63650, 63655, 63685, 64561, 64581), biofeedback (90901, 90912/90913), photodynamic therapy (96567, 96573), acupuncture series (97810‑98714), and multiple J‑codes for interferons and botulinum toxin (e.g., J0585).

    • Prior authorization/coverage review may be required when these services are proposed.
    • Use of CPT/HCPCS codes listed as 'not covered' may trigger claim denial when submitted for the indications in this CPB.
    Prior Authorization

    Prior authorization for excisional/surgical treatments

    Surgical procedures (local excision, total vestibulectomy, perineoplasty) are described as last‑resort options after failure of conservative management; prior authorization may be required to confirm documented failure of appropriate conservative therapies and localized refractory symptoms before approving surgery.

    • Documented failure of appropriate conservative therapies (topical/oral medications, physical therapy, biofeedback, guided nerve blocks) is expected prior to surgery.
    • Pain should be localized to the vestibule (e.g., cotton swab testing) and refractory to prior treatments to support excisional surgery.
    Prior Authorization

    Consider prior authorization for limited‑evidence interventions (BTX, lasers)

    Interventions with limited or preliminary evidence (for example, botulinum toxin injections and laser therapies) are noted as having insufficient evidence and may be subject to prior authorization or payer review before approval.

    • Botulinum toxin type A has limited evidence and is often not covered for this indication.
    • Laser therapies are described as having low-level evidence and are not recommended for routine practice; payer review may be required.
    Prior Authorization

    Prior authorization may be required for LI‑SWT (novel device‑based procedure)

    Low‑intensity shockwave therapy (LI‑SWT) is supported only by a single small RCT (n=32); prior authorization may be required with documentation of failed conservative therapy and submission of trial‑level outcomes to justify coverage.

    • LI‑SWT evidence limited to a small, single‑center RCT (n=32); document prior conservative therapies and objective outcome measures (VAS, algometer).
    • Prior authorization may request trial protocol details and follow‑up outcome measures.
    Prior Authorization

    Prior authorization advised for experimental/novel therapies

    Treatments described as novel or investigational (e.g., LI‑SWT, Ladylift non‑ablative laser, Meclon Lenex vulvar emulgel) have limited and preliminary evidence; prior authorization is advised and may require submission of the study/procedure protocol, prior standard therapies tried, and relevant outcome measures.

    • Submit trial protocol or device details, treatment schedule, and objective baseline/follow‑up pain scores (e.g., VAS) when requesting coverage.
    • Document prior use and failure of established noninvasive therapies (pelvic floor PT, multimodal somato‑cognitive therapy).
    Note

    No explicit prior‑auth codes specified in this bulletin

    The policy document does not list explicit prior authorization codes or state formal mandatory prior authorization requirements for these services; individual payer plan rules may still apply.

    • No specific prior authorization codes or explicit mandatory prior‑auth triggers are specified in the policy text provided.
    Step Therapy

    Require documented conservative therapy failure before surgery

    Surgery (vestibulectomy/perineoplasty) is considered after failure of conservative measures — providers should document that vulvar care, physical therapy, and appropriate pharmacotherapy (including analgesics) were tried and failed prior to proposing surgery.

    • Conservative measures (vulvar care, physical therapy, pharmacotherapy including analgesics) must have been tried and failed before vestibulectomy is considered.
    Step Therapy

    Emphasize conservative measures before surgery

    Guidelines and expert reviews emphasize trial of conservative measures — topical/oral medications, pelvic floor physical therapy, biofeedback, and guided nerve blocks — before considering surgical intervention.

    • Follow multidisciplinary conservative options (topical/oral meds, PT, biofeedback, nerve blocks) prior to invasive interventions.
    • Document response and duration of conservative treatments.
    Step Therapy

    Follow stepped care: multidisciplinary first‑line, reserve surgery/second‑line agents

    Expert guidance supports a stepped, multidisciplinary care approach and reserves surgery or second‑line agents (e.g., capsaicin, botulinum toxin, interferon) for selected patients after first‑line therapies fail.

    • Multidisciplinary care (psychological therapies, pelvic floor PT) is first‑line.
    • Second‑line or conditional therapies should be reserved for refractory cases and have limited evidence.
    Step Therapy

    Stepwise preference for non‑pharmacologic interventions and selective surgery

    Non‑pharmacological interventions (psychological therapy, pelvic floor physical therapy) are preferred first‑line options, with selective use of surgery for provoked vestibulodynia when indicated.

    • Consider psychological interventions and pelvic floor PT before experimental therapies.
    • Vestibulectomy supported as an option for provoked vestibulodynia after conservative care fails.
    Step Therapy

    Recommend conservative therapy prior to novel interventions

    Before offering novel interventions, consider established noninvasive therapies such as pelvic floor physical therapy and multi‑modal somato‑cognitive therapy; these should be attempted prior to approving experimental treatments.

    • Document completion and response to physiotherapy‑based interventions prior to novel device or drug interventions.
    • Recommend conservative, evidence‑supported noninvasive therapies before experimental options.
    Note

    No formal step‑therapy mandates specified

    The document does not specify formal step‑therapy program requirements or mandated step edits; it notes recommended sequencing but lists no enforceable step‑therapy rules in these excerpts.

    • No explicit payer step‑therapy requirements are specified in the policy text provided.
    Documentation Required

    Document diagnosis and prior conservative therapy failure to support surgical necessity

    When proposing surgery, clinical documentation should explicitly support the diagnosis (vulvodynia/vulvar vestibulitis) and record that appropriate conservative measures were tried and failed to justify medical necessity for excisional procedures.

    • Include documentation of prior conservative therapies attempted and their outcomes.
    • Record examination findings confirming diagnosis and localization of pain.
    Documentation Required

    Document cotton‑swab localization and prior therapy failure

    Document localization of painful vestibular areas (e.g., cotton‑swab testing) and note prior failure of conservative therapies; cotton‑swab testing is described as part of preoperative localization and supports excisional surgery decisions.

    • Record cotton‑swab test localization and correspondence to planned excision area.
    • Include prior treatment history showing lack of adequate response.
    Documentation Required

    Document VAS and cotton‑swab test outcomes for ESWT/LI‑SWT

    For ESWT/LI‑SWT outcomes, document baseline and follow‑up VAS pain scores and cotton‑swab test (CST) where used; the ESWT RCT reported >30% pain reductions at 1, 4, and 12 weeks in the treatment group.

    • Record VAS and CST scores at baseline and at follow‑up intervals (1, 4, 12 weeks for ESWT).
    • Provide objective measures (algometer, CST) where available to support clinical effect.
    Documentation Required

    Document VAS, dyspareunia, vestibular health indices for laser therapies

    Laser therapy study reports commonly document VAS pain scores, dyspareunia scores, vestibular health indices, and patient‑reported improvement and satisfaction; include these measures for any coverage request.

    • Collect VAS, Marinoff dyspareunia scores, vestibular health index, and patient global impression measures for laser treatments.
    • Note that laser study protocols and reporting were heterogeneous.
    Documentation Required

    Document imaging guidance, agents, and pain scores for ganglion impar block

    For ganglion impar block, document imaging guidance (CT vs fluoroscopy), approach, agents administered, pre‑ and post‑procedure pain scores, and number/timing of infiltrations to support the claim.

    • Specify imaging modality used and needle approach.
    • Report VAS before, immediately after, and at follow‑up (e.g., Day 15) and the number of infiltrations.
    Documentation Required

    Required clinical documentation elements for novel/experimental therapies

    Clinical documentation supporting investigational or novel interventions should include baseline and follow‑up pain scores (e.g., VAS), objective measures used in studies (algometer, CST, FSFI), and detailed treatment protocol elements (device, waveform, medication concentration, session frequency) and follow‑up duration.

    • Provide objective outcome measures (algometer readings, FSFI, Wong‑Baker) and VAS at specified intervals.
    • Include full treatment protocol details (device model, energy settings, number/frequency of sessions) and duration of follow‑up.
    Denial Risk

    Denial risk for claims based solely on small preliminary studies

    Claims submitted for interventions supported only by small, preliminary studies (small sample sizes, short follow‑up) may be at risk for denial if higher‑level evidence or longer‑term data are required by the payer.

    • Evidence described as preliminary (small n and limited follow‑up) increases risk of coverage denial if stronger evidence is requested.
    • Consider including more robust outcome data and longer follow‑up when requesting coverage.
    Denial Risk

    Potential denial risk when submitting listed not‑covered CPT/HCPCS codes

    Use of CPT/HCPCS codes enumerated as 'not covered' in this bulletin (examples: 0101T, 56800, 63650, 63655, 63685, 64520, 64550, 64561, 64581, 64614, 64630, 64646‑64647, 90867‑90869, 90880, 90901, 90912‑90913, 96567, 96573, 97810‑98714) may trigger claim denial when submitted for the indications listed in this CPB.

    • Confirm coding and medical necessity prior to submission; these codes are listed as not covered for the CPB indications.
    • Prior authorization or exception process may be required if locally permitted.
    Denial Risk

    Denial risk: vestibuloplasty ineffective

    Vestibuloplasty (denervation without excision) has been shown to be ineffective and procedures with known poor outcomes may be denied as not medically necessary.

    • Avoid proposing vestibuloplasty as it is reported to be ineffective.
    • Expect denials for procedures with demonstrated poor outcomes.
    Denial Risk

    Coverage limitation: botulinum toxin often not covered for vulvodynia

    Insurance coverage for botulinum toxin type A for vulvodynia is typically limited and often not covered when used for this indication; providers should anticipate coverage restrictions or denials.

    • Botulinum toxin is described as expensive and typically not covered for vulvodynia.
    • Provide strong supporting documentation and rationale if requesting coverage.
    Denial Risk

    Denial risk: laser not routinely recommended for vulvodynia

    Laser therapies for vulvodynia or lichen sclerosus are not recommended for routine clinical practice outside well‑designed clinical trials or special governance arrangements; expect payer scrutiny and potential denial for routine use.

    • Laser should be limited to clinical trials or special governance settings per best‑practice guidance.
    • Routine clinical claims for laser therapies may be reviewed and potentially denied.
    Denial Risk

    Denial risk from laser evidence limitations and protocol heterogeneity

    Heterogeneous and poorly reported laser protocols with limited follow‑up make effectiveness uncertain; lack of standardized protocols may lead to requests for additional evidence or coverage denial.

    • Provide standardized protocol details and longer‑term follow‑up when seeking coverage for laser therapies.
    • Heterogeneous parameters and reporting increase likelihood of documentation requests or denial.
    Denial Risk

    Denial risk for therapies supported only by small, short‑term studies

    Because many studies cited are small and short‑term, claims for therapies supported only by these preliminary data may be at risk for denial if payers require higher‑level evidence or longer follow‑up.

    • Small sample sizes and limited observation periods increase risk of denial for investigational therapies.
    • Include larger trial data or extended follow‑up where available to reduce denial risk.
    Note

    Background on Condition and Treatments

    Vulvodynia is defined as chronic vulvar discomfort (burning, stinging, irritation, or rawness) present for more than 3 months in the absence of other dermatologic or gynecologic causes. It is classified by site (localized versus generalized) and by whether pain is provoked, unprovoked, or mixed; diagnosis commonly relies on history, exclusion of other causes, and physical assessment such as the cotton‑swab test to localize vestibular pain.

    Definitions and Terminology

    inv-51: Vulvodynia — chronic vulvar discomfort including burning, stinging, irritation, or rawness for >3 months
    DefinitionChronic vulvar discomfort (burning, stinging, irritation, or rawness) lasting more than 3 months
    ClassificationSubcategorized by site (localized vs generalized) and provocation (provoked, unprovoked, mixed)
    Diagnosis considerationsMade after history, exclusion of infections/dermatologic causes, and pain elicited by light pressure (e.g., cotton swab test)
    inv-52: Vestibulitis / Localized provoked vulvodynia (LPV) — localized type often identified with cotton swab test
    Alternate nameVestibulitis (previous term) / Localized provoked vulvodynia (LPV)
    Clinical differentiationTypically differentiated from generalized vulvodynia using the cotton swab test
    ProvocationPain is provoked by touch or pressure to the vestibule (e.g., during intercourse or tampon use)
    inv-53: Total vestibulectomy / local excision / perineoplasty — surgical categories and brief descriptions
    Local excisionShallow excision of precisely localized small painful vestibular areas
    Total vestibulectomyRemoval of vestibular tissue (may extend from peri‑urethral area to the perineum), often outpatient under spinal or general anesthesia
    PerineoplastyCombination of vestibulectomy with removal/repair of perineal tissue, usually terminating above the anal orifice
    inv-54: Radiofrequency ablation (RFA) variants — conventional, cooled, pulsed described
    Conventional (thermal) RFAUses continuous radiofrequency-generated heat to destroy pain-conducting nerve fibers
    Cooled RFAEmploys circulating cooling within the probe to create a larger lesion while limiting thermal injury to surrounding tissues
    Pulsed RFADelivers short bursts of radiofrequency current (allowing tissue cooling between bursts) to reduce the risk of collateral tissue destruction
    inv-55: Radiofrequency ablation/denervation (cooled and pulsed) — nerve destruction/modulation descriptions
    MechanismDestruction or modulation of nerves using heat (conventional/cooled) or pulsed radiofrequency bursts to reduce pain signaling
    Cooled RFA rationaleCooling allows targeting a larger tissue volume without excessive thermal injury
    Pulsed RFA rationalePulsed delivery reduces continuous thermal exposure, aiming to modulate rather than destroy tissue
    inv-56: Extracorporeal shock-wave therapy (ESWT) — non-invasive focused shock waves and study outcomes
    TechniqueNon-invasive delivery of focused shock waves to tissues (perineal application described)
    Trial protocol exampleWeekly perineal ESWT: 3,000 pulses × 4 weeks; energy flux density 0.25 mJ/mm2; frequency 4 Hz; follow-ups at 1, 4, and 12 weeks
    Reported outcomesRandomized, double‑blind RCT (n=62) found significant reductions in VAS pain and cotton‑swab test scores in the treatment group versus placebo
    inv-57: Micro-ablative fractional CO2 / Er:YAG laser and High-intensity laser therapy (HILT) — energy-based therapies and evidence caveats
    ModalitiesMicro‑ablative fractional CO2, Er:YAG lasers, and high‑intensity laser therapy (HILT) applied to vulvar/vaginal tissues
    Proposed effectEnergy-based tissue remodeling purported to improve vestibular health and reduce pain
    Evidence caveatsStudies are heterogeneous, often nonrandomized or small, industry‑sponsored, with short follow-up; long‑term safety and standardized protocols are lacking
    inv-58: Ganglion impar — anatomical description and relevance to perineal pain interventions
    Anatomical locationFused terminus of the sympathetic chain located anterior to the sacrococcygeal junction
    Innervation territoryInnervates the perineum, distal rectum, distal vagina, distal urethra, and anus
    Clinical relevanceTarget for block/infiltration in perineal pain management (ganglion impar block / impar node infiltration)
    inv-59: Provoked vestibulodynia (PVD) — definition and clinical features
    DefinitionLocalized vulvar vestibular pain provoked by touch or pressure (e.g., intercourse, tampon use)
    Associated featuresOften associated with dyspareunia, negative effects on sexual function and quality of life
    Diagnosis supportProvoked vestibulodynia is commonly identified by pain elicited on light pressure (cotton swab test) and by exclusion of other causes

    Policy Revision History

    2008-07-01policy_effective

    Policy effective date established.

    201?unknown

    [removed placeholder — no such entry]

    2023-10-26policy_reviewLatest

    Policy most recently reviewed on 10/26/2023.